Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2025 Earnings Call Transcript
Operator: Good morning, and welcome to Intellia' First Quarter 2025 Financial Results Conference Call. My name is Drew, and I will be your conference operator today.
Intellia Therapeutics Inc. (NTLA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 13,011,015 | $92,508,319 | +4% | 0.93% |
| 2. | Citadel Investment Group Ken Griffin | 2,757,568 | $19,606,308 | +11% | 0% |
| 3. | Contrarius Investment Management Stephen Mildenhall | 2,021,040 | $14,369,594 | +100% | 0.98% |
| 4. | Casdin Capital Eli Casdin | 2,000,000 | $14,220,000 | 1.16% | |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 1,982,317 | $14,094,274 | -1% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.50 | 4,250 | Officer | 7,500 | 2019-03-06 | Filing | |
| $16.00 | 3,250 | Officer | 3,250 | 2019-03-06 | Filing | |
| $18.00 | 58,534 | Director | 2,662,180 | 2016-05-11 | Filing | |
| $18.00 | 191,466 | Director | 2,603,646 | 2016-05-11 | Filing | |
| $18.00 | 300,000 | Large Shareholder | 790,527 | 2016-05-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.50 | 265 | 19,203 | 2025-04-29 | Filing | ||
| $8.99 | 679 | 95,369 | 2025-03-04 | Filing | ||
| $8.99 | 2,572 | 111,925 | 2025-03-04 | Filing | ||
| $9.97 | 265 | 19,468 | 2025-01-29 | Filing | ||
| $12.18 | 1,372 | 45,640 | 2025-01-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,752,031 | $76,446,941 | 0% | |
| 2. | 10,556,190 | $75,054,514 | 0% | |
| 3. | 4,510,261 | $32,067,956 | 0% | |
| 4. | 3,801,695 | $27,030,056 | 0% | |
| 5. | 3,779,424 | $26,871,705 | 0.01% |
News See All
10 Stocks Under $10 that Will Triple
As we delve into the discussion on stocks that will triple, we must shed light on the U.S.
8 Best Gene-Editing Stocks to Buy
Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to treat or prevent diseases.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2024 Earnings Call Transcript
Operator: Good morning, and welcome to Intellia Therapeutics' Fourth Quarter and Full-Year 2024 Financial Results Conference Call. My name is Drew, and I will be your conference operator today.
Cathie Wood's Stock Portfolio: 2025 Stock Picks
Cathie Wood is one of Wall Street's most contentious figures.
Top 11 CRISPR Stocks to Invest In
The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical challenges, and leveraging cutting-edge technologies like pharmacogenomics, digital...
10 Best Gene Therapy Stocks to Buy Right Now
Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat or prevent disease.
10 Worst ARK Stocks To Buy According to Short Sellers
Cathie Wood of ARK Investment is one of Wall Street's most well-known hedge fund bosses.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q3 2024 Earnings Call Transcript
Operator: Good morning and welcome to Intellia Therapeutics’ Third Quarter 2024 Financial Results Conference Call. My name is Drew and I will be your conference operator today.
10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds
The pharmaceutical industry remains a hub of patent innovation, driven by evolving treatment paradigms, unmet medical needs, and the rising influence of technologies like pharmacogenomics, digital therapeutics...
Billionaire Hedge Funds
